EGFR and non-small cell lung carcinoma: Although patients in the DDR‐activated subgroup had a poorer prognosis than those in the DDR‐suppressed subgroup, they had more frequent gene mutations, higher TMB and TME scores, and a more inflammatory composition of immune cells, indicating that NSCLC patients with some DDR gene subtypes may still respond to immunotherapy even if they harbor EGFR‐sensitive mutations.